AUTL — Autolus Therapeutics Share Price
0.000.00%
Last trade - 00:00- $399.21m
- $189.56m
- $10.12m
- 19
- 25
- 67
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.15 | ||
| Price to Tang. Book | 1.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.39% | ||
| Return on Equity | -52.1% | ||
| Operating Margin | -902.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.72 | 2.33 | 6.36 | 1.7 | 10.12 | 73.58 | 153.95 | 28.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- February 2nd, 2018
- Public Since
- June 22nd, 2018
- No. of Shareholders
- 33
- No. of Employees
- 647
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 266,141,411
- Address
- The Mediaworks, 191 Wood Lane, LONDON, W12 7FP
- Web
- https://www.autolus.com/
- Phone
- +44 2038296230
- Contact
- Lucinda Crabtree
- Auditors
- Ernst & Young LLP
Upcoming Events for AUTL
Similar to AUTL
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Autolus Therapeutics share price?
As of Today at 19:25 UTC, shares in Autolus Therapeutics are trading at $1.50. This share price information is delayed by 15 minutes.
How has the Autolus Therapeutics share price performed this year?
Shares in Autolus Therapeutics last closed at $1.50 and the price had moved by -60.63% over the past 365 days. In terms of relative price strength the Autolus Therapeutics share price has underperformed the S&P500 Index by -65.58% over the past year.
What are the analyst and broker recommendations for Autolus Therapeutics?
The overall consensus recommendation for Autolus Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Autolus Therapeutics dividend yield?
Autolus Therapeutics does not currently pay a dividend.
Does Autolus Therapeutics pay a dividend?
Autolus Therapeutics does not currently pay a dividend.
When does Autolus Therapeutics next pay dividends?
Autolus Therapeutics does not currently pay a dividend.
How do I buy Autolus Therapeutics shares?
To buy shares in Autolus Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Autolus Therapeutics?
As of the previous close price of $1.50, shares in Autolus Therapeutics had a market capitalisation of $399.21m.
Where are Autolus Therapeutics shares listed?
Here are the trading details for Autolus Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AUTL
What kind of share is Autolus Therapeutics?
Based on an overall assessment of its quality, value and momentum Autolus Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Autolus Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Autolus Therapeutics is $9.46. That is 530.67% above the last closing price of $1.50.
Analysts covering Autolus Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.87 for the next financial year.
Find out moreWhat is the trend in the Autolus Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Autolus Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -21.49%.
As of the last closing price of $1.50, shares in Autolus Therapeutics were trading -28.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Autolus Therapeutics PE Ratio?
The Autolus Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Autolus Therapeutics?
We do not have data on Autolus Therapeutics' directors